English   español  
Please use this identifier to cite or link to this item: http://hdl.handle.net/10261/34716
Share/Impact:
Statistics
logo share SHARE logo core CORE   Add this article to your Mendeley library MendeleyBASE

Visualizar otros formatos: MARC | Dublin Core | RDF | ORE | MODS | METS | DIDL
Exportar a otros formatos:

Title

Limitations to enhancing the speed of onset of antidepressants. Are rapid action antidepressants possible?

AuthorsArtigas, Francesc
Keywords5-HT1A receptors
Antidepressants
Clinical trials
Pindolol
Selective serotonin reuptake inhibitors (SSRIs)
Serotonin
Issue DateJan-2001
PublisherJohn Wiley & Sons
CitationHuman Psychopharmacology - Clinical and Experimental 16(1): 29-36 (2001)
AbstractExisting antidepressant treatments suffer from a limited efficacy and a slow onset of action. Some first-generation antidepressant drugs are still among the most effective treatments. Several neurobiological adaptive mechanisms are involved in the delayed action of antidepressants. Among these, a negative feed-back involving somatodendritic autoreceptors plays an important role in such delay. In the case of the SSRIs, the prevention of this effect with 5-HT1A autoreceptor antagonists enhances their effects at experimental level. Open-label and placebo-controlled trials with the mixed β-adrenoceptor/5-HT1A antagonist pindolol support that this agent reduces the latency to achieve a clinical improvement when used in combination with SSRIs. Displacement studies support that this action is mediated by its interaction with 5-HT1A receptors. The design of clinical trials for the evaluation of fast-acting antidepressants is critical. The use of loose criteria of response may result in a poor discriminating power. Conversely, stringent clinical criteria may be more helpful in revealing the differences between treatments. The data of a double-blind, placebo-controlled trial comparing fluoxetine plus placebo and fluoxetine plus pindolol suggests that the use of sustained response (i.e., one maintained until the end of the trial) is critical for the establishment of differences between treatments. Other factors, such as a placebo lead-in phase or the frequency of visits, appear to play a minor role. Overall, these data indicate that faster antidepressant drugs can be obtained through a better knowledge of their actions in CNS.
Publisher version (URL)http://dx.doi.org/10.1002/hup.180
URIhttp://hdl.handle.net/10261/34716
DOI10.1002/hup.180
ISSN0885-6222
E-ISSN1099-1077
Appears in Collections:(IIBB) Artículos
Files in This Item:
File Description SizeFormat 
accesoRestringido.pdf15,38 kBAdobe PDFThumbnail
View/Open
Show full item record
Review this work
 

Related articles:


WARNING: Items in Digital.CSIC are protected by copyright, with all rights reserved, unless otherwise indicated.